|
114
|
PCDH7, NRXN3, TPTE/ PTEN2, EPHA3, TSPY, HGF, PKIA, PRLR, NR2F1, TNS, MET, CALN1, ADAM-TS3, NPL4, MYO3A, GNA11, GAGEB1/PA GE1, AKAP9, TCF4, MYLK, KLK2, HOXA10, DDR2, EGF, TEM8, XAGE-1, GAS2.
|
mRNA
|
Humans
|
Upregulated (Log2 fold change: 2-7.9 fold)
|
Prognostic
|
Androgen Independent PCa Vs Androgen Dependent PCa
|
NA
|
Cell Lines
|
17977648
|
|
115
|
ANGPT2, THBS1, CCL5, PTK6, CXCL11, S100P, PSMD5, CDKN2B, PEG3, HTATIP2, CXCL2, RND1, NK4, ACPP, ICAM1, FOSL2, SFN, PLAT, INHBE, CDKN1C, TP73, SOCS2, BMPR1B, CCL2, VIM, SPRY2, CXCL10, LCN2, AKAP12, KLF4, ATF3, FBN1, TWIST1, ALCAM, MSX2, LOX, BTG1, SOCS1, PPP3CA, PPP3CA
|
mRNA
|
Humans
|
Downregulated (Log2 fold change: 1.3-7.8 fold)
|
Prognostic
|
Androgen Independent PCa Vs Androgen Dependent PCa
|
NA
|
Cell Lines
|
17977648
|
|
215
|
Endothelial cell-specific molecule 1; Protein tyrosine phosphatase receptor type-Q, CD24 antigen; Gap junction membrane channel protein alpha 1; Transmembrane 4 superfamily member 3; Serpine2; Activated leukocyte cell adhesion molecule; Fibromodulin; Plasminogen activator inhibitor 2 type A; Kelch repeat and BTB (POZ) domain containing 10 (krp1); Preproenkephalin, related sequence; Sialophorin; Thymosin beta-4; Glutamate receptor interacting protein 1; Synuclein, gamma; Hypoxanthine guanine phosphoribosyl transferase; Phosphoribosyl pyrophosphate synthetase 1; Phosphoribosyl pyrophosphate synthetase 2; UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6; Dual specificity phosphatase 5; Cytochrome P450, family 3, subfamily a, polypeptide 13; 3-hydroxy-3-methylglutaryl-Coenzyme A reductase ; Branched chain keto acid dehydrogenase E1, beta polypeptide; Cytochrome P450, subfamily 24; Plasminogen activator, urokinase; Caveolin 1; Cyclin D1; High mobility group AT-hook 1; Cxxc5; HNF-3/forkhead homolog-1; Fatty acid binding protein 4, adipocyte; Fatty acid binding protein 5, epidermal; Rabin 3; Phospholipase C, delta 4; Decay-accelarating factor; Coagulation factor II (thrombin) receptor-like 1; Nerve growth factor receptor associated protein 1; Asparagine synthetase; Dual specificity phosphatase 6; Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform; Protein tyrosine phosphatase, receptor type, N1; UDP glycosyltransferase 1 family polypeptide A2; Adenosine monophosphate deaminase 3; Stearoyl-Coenzyme A desaturase 1; Hypothetical LOC290595 (LOC290595), mRNA; Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA; Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA; Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds;
|
mRNA
|
Rat
|
Upregulated (Endothelial cell-specific molecule 1 (26.5 fold); Protein tyrosine phosphatase receptor type Q (19.72 fold); CD24 antigen (15.56 fold); Gap junction membrane channel protein alpha 1 (10.53 fold); Transmembrane 4 superfamily member 3 (10.4 fold); Serpine2 (8.61 fold); Activated leukocyte cell adhesion molecule (6.65 fold) ; Fibromodulin (2.62 fold); Plasminogen activator inhibitor 2 type A (2.11 fold); Kelch repeat and BTB (POZ) domain containing 10 (krp1) (36.21 fold); Preproenkephalin, related sequence (24.63 fold); Sialophorin1 (24.14 fold); Thymosin beta-4 (19.82 fold) ; Glutamate receptor interacting protein 1 (8.4 fold) ; Synuclein, gamma (6.62 fold); Hypoxanthine guanine phosphoribosyl transferase (11.45 fold); Phosphoribosyl pyrophosphate synthetase 1 (8.25 fold) ; Phosphoribosyl pyrophosphate synthetase 2 (5.37 fold); UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6 (3.4 fold); Dual specificity phosphatase 5 (2.35 fold); Cytochrome P450, family 3, subfamily a, polypeptide 13 (14.28 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (3.49 fold) ; Branched chain keto acid dehydrogenase E1, beta polypeptide (2.14 fold); Cytochrome P450, subfamily 24 (2.11 fold); Plasminogen activator, urokinase (4.68 fold); Caveolin 1 (31.05 fold) ; Cyclin D1 (7.95 fold); High mobility group AT-hook 1 (15.41 fold) ; Cxxc5 (4.25 fold); HNF-3/forkhead homolog-1 (3.08 fold); Fatty acid binding protein 4, adipocyte (34.02 fold); Fatty acid binding protein 5, epidermal (15.38 fold) ; Rabin 3 (6.46 fold); Phospholipase C, delta 4 (2.64 fold); Decay-accelarating factor (4.02 fold); Coagulation factor II (thrombin) receptor-like 1 (4.96 fold); Nerve growth factor receptor associated protein 1 (8.75 fold); Asparagine synthetase (14.65 fold); Dual specificity phosphatase 6 (11.08 fold); Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (2.31 fold) ; Protein tyrosine phosphatase, receptor type, N1 (2.22 fold); UDP glycosyltransferase 1 family polypeptide A21 (5.93 fold); Adenosine monophosphate deaminase 3 (2.14 fold); Stearoyl-Coenzyme A desaturase 1 (25.92 fold); Hypothetical LOC290595 (LOC290595), mRNA (8.46 fold); Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA (4.76 fold); Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA (3.58 fold); Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds (3.38 fold);
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p<0.005
|
Cell Lines
|
17713630
|
|
216
|
Procollagen, type XII, alpha 1; Glycoprotein Ib (platelet), beta polypeptide; Macrophage stimulating 1 (hepatocyte growth factor-like); Alpha-2-macroglobulin; Hyaluronan and proteoglycan link protein 1; Glycoprotein 38; Decorin; Vascular cell adhesion molecule 1; Clusterin; Elastin; Biglycan; Selenoprotein P, plasma, 1; T-cell receptor gamma chain; Myxovirus (influenza virus) resistance 2; Major histocompatibility complex, class II, DM alpha; MHC class Ib RT1.S3; RT1 class Ib, locus Aw2; Similar to interferon regulatory factor 7 (LOC293624), mRNA; Late gestation lung protein 1; Transgelin; Ectonucleoside triphosphate diphosphohydrolase 2; Dual specificity phosphatase 1; Cytochrome b-245, alpha polypeptide; 3-alpha-hydroxysteroid dehydrogenase; Cathepsin S; Alanyl (membrane) aminopeptidase; Dipeptidase 1 (renal); Caspase 1; B-cell translocation gene 3; CD 81 antigen; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; LIM homeobox protein 2; Lectin, galactose binding, soluble 9; apolipoprotein E; Ubiquitin carboxy-terminal hydrolase L1; Parvalbumin; Purkinje cell protein 4; Carboxylesterase 1; O-6-methylguanine-DNA methyltransferase; UDP glycosyltransferase 1 family, polypeptide A6; Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5; Growth hormone receptor; Insulin-like growth factor 1; Insulin-like growth factor binding protein 5; Peripherin 1; Arginosuccinate synthetase; Lactate dehydrogenase B; Calcium/calmodulin-dependent serine protein kinase; Aminolevulinic acid synthase 1; 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2; Alcohol Dehydrogenase 1; Phosphodiesterase 3B; Similar to kelch domain containing 3; testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA; Similar to cornichon-like protein (LOC361705), mRNA; Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA; Similar to CLN6 protein (LOC315746), mRNA; Reticulocalbin 3; Similar to CG31613-PA (LOC364716), mRNA;
|
mRNA
|
Rat
|
Downregulated (Procollagen, type XII, alpha 1 (2.18 fold); Glycoprotein Ib (platelet), beta polypeptide (2.5 fold); Macrophage stimulating 1 (hepatocyte growth factor-like) (2.61 fold); Alpha-2-macroglobulin (3.8 fold); Hyaluronan and proteoglycan link protein 1 (3.82 fold); Glycoprotein 38 (3.87 fold); Decorin (5.74 fold); Vascular cell adhesion molecule 1 (7.82 fold); Clusterin (8.84 fold); Elastin (12.76 fold); Biglycan (13.23 fold); Selenoprotein P, plasma, 1 (23.08 fold); T-cell receptor gamma chain (2.2 fold); Myxovirus (influenza virus) resistance 2 (2.22 fold) ; Major histocompatibility complex, class II, DM alpha (2.37 fold); MHC class Ib RT1.S3 (4.8 fold) ; RT1 class Ib , locus Aw2 (5.18 fold); Similar to interferon regulatory factor 7 (LOC293624), mRNA (6.14 fold); Late gestation lung protein 1 (2.26 fold); Transgelin (5.72); Ectonucleoside triphosphate diphosphohydrolase 2 (2.7 fold); Dual specificity phosphatase 1 (2.3 fold); Cytochrome b-245, alpha polypeptide (3.64 fold); 3-alpha-hydroxysteroid dehydrogenase (4.86 fold); Cathepsin S (2.33 fold); Alanyl (membrane) aminopeptidase (3.18 fold); Dipeptidase 1 (renal) (6.82 fold); Caspase 1 (11.12 fold); B-cell translocation gene 3 (17.35 fold); CD 81 antigen (36 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.28 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.62 fold); LIM homeobox protein 2 (5.43 fold); Lectin, galactose binding, soluble 9 (2.46 fold); apolipoprotein E (29.52 fold); Ubiquitin carboxy-terminal hydrolase L1 (16.29 fold); Parvalbumin (3.85 fold); Purkinje cell protein 4 (6.82 fold); Carboxylesterase 1 (2.16 fold); O-6-methylguanine-DNA methyltransferase (4.62 fold); UDP glycosyltransferase 1 family, polypeptide A6 (3.25 fold); Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5 (2.27 fold); Growth hormone receptor (3.12 fold); Insulin-like growth factor 1 (4.85 fold); Insulin-like growth factor binding protein 5 (5.25 fold); Peripherin 1 (7.17 fold); Arginosuccinate synthetase (12.75 fold); Lactate dehydrogenase B (15.07 fold); Calcium/calmodulin-dependent serine protein kinase (4.13 fold); Aminolevulinic acid synthase 1 (2.39 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (3.17 fold); Alcohol Dehydrogenase 1 (6.38 fold); Phosphodiesterase 3B (4.76 fold); Similar to kelch domain containing 3 testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA (2.17 fold); Similar to cornichon-like protein (LOC361705), mRNA (2.35 fold); Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA (2.81 fold); Similar to CLN6 protein (LOC315746), mRNA (3.68 fold); Reticulocalbin 3 (3.94 fold); Similar to CG31613-PA (LOC364716), mRNA (8.61 fold);
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p<0.005
|
Cell Lines
|
17713630
|
|
217
|
Kelch repeat and BTB (POZ) domain containing 10 (krp1)
|
mRNA
|
Rat
|
Upregulated in MAT-LyLu (48 fold)
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p=0.01816
|
Cell Lines
|
17713630
|
|
218
|
Endothelial cell-specific molecule 1
|
mRNA
|
Rat
|
Upregulated in MAT-LyLu (23 fold)
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p=0.00995283
|
Cell Lines
|
17713630
|
|
219
|
Caveolin 1
|
mRNA
|
Rat
|
Upregulated in MAT-LyLu (45 fold)
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p=0.0009527
|
Cell Lines
|
17713630
|
|
236
|
Cytokeratin 5 (CK5)
|
mRNA
|
Humans
|
Upregulated in Dasatinib Sensitive Cell Lines (>3 fold)
|
Potential Predictive
|
Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines
|
p<0.05
|
Cell Lines
|
18047674
|
|
237
|
Prostate Specific Antigen (PSA)
|
mRNA
|
Humans
|
Downregulated in Dasatinib Sensitive Cell Lines (>3 fold)
|
Potential Predictive
|
Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines
|
p<0.05
|
Cell Lines
|
18047674
|
|
238
|
Androgen Receptor (AR)
|
mRNA
|
Humans
|
Downregulated in Dasatinib Sensitive Cell Lines (>3 fold)
|
Potential Predictive
|
Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines
|
p<0.05
|
Cell Lines
|
18047674
|
|
442
|
ACPP; AD-017; AMIGO2; APPBP2; ASNS; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10; C1orf9; C22orf18 (CENPM); C5orf13; C6orf111; C6orf210; C9orf116; C9orf127; CATSPER2; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2; CDC20; CDC25C; CDC6; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1; EFNB2; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1; GALNT7; GFPT1; GGA2; GTSE1; GTSE1; H2AFX; H2AFY; HCAP-G; HCAP-G; HECA; HMGB2; HMMR; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A KLK2; KLK2; KLK3; KNS2; KNTC2; LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5 ; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10; MYRIP; NAP1L3; NAV3; NEK2; NEK2 NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A; PDIR; PER3; PIK3R1;PINK1; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B; RACGAP1; RBM30; RFC3; RRM1 ; RRM2; RRM2; SAS; SDC2 ; SDC2 ; SDC4; SEC6L1; SHCBP1 ; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2; STK3; STK6 ; TM4SF1; TMPO; TNFRSF10B ; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK; TPBG; TPX2; TRIB1; TTC3; TUBA3; TYMS; UAP1; UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Metastatic Vs Localised Prostate Cancer
|
p=0.0000121714
|
Cell Lines
|
19351846
|
|
443
|
ACPP; AD-017 ; AMIGO2; APPBP2; ASNS ; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10 ; C1orf9; C22orf18 (CENPM) ; C5orf13; C6orf111 ; C6orf210; C9orf116 ; C9orf127; CATSPER2 ; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2 ; CDC20; CDC25C ; CDC6 ; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1 ; EFNB2 ; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1 ; GALNT7; GFPT1 ; GGA2; GTSE1; GTSE1 ; H2AFX ; H2AFY; HCAP-G; HCAP-G ; HECA; HMGB2; HMMR ; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A; KLK2 ; KLK2 ; KLK3; KNS2 KNTC2 LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10 MYRIP; NAP1L3; NAV3 ; NEK2; NEK2; NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A ; PDIR; PER3 ; PIK3R1 ; PINK1 ; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B ; RACGAP1;RBM30; RFC3; RRM1; RRM2; RRM2; SAS ; SDC2; SDC2 ; SDC4; SEC6L1; SHCBP1; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2 ; STK3; STK6; TM4SF1 ; TMPO; TNFRSF10B; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK ; TPBG; TPX2; TRIB1 ; TTC3; TUBA3; TYMS; UAP1;UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Androgen Dependent Vs Androgen Independent Prostate Cancer
|
p=0.0056
|
Cell Lines
|
19351846
|
|
454
|
MIC-1 (Macrophage inhibitory cytokine 1); A1BG a-1B-glycoprotein1 precursor; VTNC (Vitronectin precursor); RNPEP (Arginyl aminopeptidase); FETUA (Fetuin A)
|
Protein
|
Humans
|
Upregulated in Docetaxel- resistant PC3-Rx cells [(MIC-1 Macrophage inhibitory cytokine 1 (2.4 fold); A1BG a-1B-glycoprotein1 precursor (1.9 fold) ; VTNC Vitronectin precursor (1.7 fold); RNPEP Arginyl aminopeptidase (1.6 fold); FETUA Fetuin A (1.6 fold)]
|
Potential Predictive
|
Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells
|
p<0.05
|
Cell Lines
|
19773444
|
|
455
|
CYR61 (Angiogenic inducer 61); MASPIN (Serpin peptidase inhibitor); AGR2 (Anterior gradient 2 homologue);
|
Protein
|
Humans
|
Downgregulated in Docetaxel- resistant PC3-Rx cells [(CYR61 Angiogenic inducer 61 (1.5 fold); MASPIN Serpin peptidase inhibitor (1.5 fold); AGR2 Anterior gradient 2 homologue (2.4 fold)];
|
Potential Predictive
|
Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells
|
p<0.05
|
Cell Lines
|
19773444
|
|
477
|
PHD1 (prolyl-4-hydroxylases 1)
|
Protein
|
Humans
|
Increased expression in Biochemical Recurrence
|
Prognostic
|
PSA recurrence Vs No PSA recurrence
|
p <0.001
|
Cell Lines
|
19854473
|
|
514
|
Enhancer of Zeste 2 (EZH2)
|
mRNA
|
Humans
|
Overexpression leads to aggressive behaviour in Cell Lines
|
Prognostic
|
Overexpression Vs No Overexpression in Cell Lines
|
NA
|
Cell Lines
|
20087897
|
|
597
|
Engrailed-2 (EN2)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Cell Lines
|
21364037
|
|
699
|
KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8 ;
|
Protein
|
Humans
|
Upregulated (Atleast 2 fold): [KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8;]Downregulated (Atleast 0.5 fold): [KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;]
|
Prognostic
|
CD44+ Vs CD44- Cells
|
p<0.05
|
Cell Lines
|
21820414
|
|
700
|
Cofilin
|
Protein
|
Humans
|
Upregulated in CD44++ Cells
|
Prognostic
|
CD44+ Vs CD44- Cells
|
p<0.01
|
Cell Lines
|
21820414
|
|
701
|
Annexin A5
|
Protein
|
Humans
|
Upregulated in CD44++ Cells
|
Prognostic
|
CD44+ Vs CD44- Cells
|
p<0.05
|
Cell Lines
|
21820414
|
|
1029
|
miR-30d
|
miRNA
|
Humans
|
Upregulated in PCa Cell Lines (> 2 fold)
|
Diagnostic
|
Normal Vs Cancerous Prostate Cell Lines
|
p<0.05
|
Cell Lines
|
23231923
|
|
1076
|
3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); chromosome 6 open reading frame 115 ( C6orf115 ); hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); S100 calcium binding protein P ( S100P ); dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); monoamine oxidase B ( MAOB ); thymidine phosphorylase ( TYMP ); monoamine oxidase A ( MAOA ); sequestosome 1 ( SQSTM1 ); tropomyosin 1 (alpha) ( TPM1 ); cathepsin D ( CTSD ); growth differentiation factor 15 ( GDF15 ); arginase, type II ( ARG2 ); glutaminase ( GLS ); arylacetamide deacetylase-like 1 ( AADACL1 ); aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); spermatogenesis associated, serine-rich 2-like ( SPATS2L ); N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); calpain 2, (m/II) large subunit ( CAPN2 ); acyl-CoA thioesterase 9 ( ACOT9 ); keratin 18 ( KRT18 ); epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); glutathione S-transferase kappa ( GSTK1 ); aldo-keto reductase family 1, member C2 ( AKR1C2 ); acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); mannosidase, beta A, lysosomal ( MANBA ); vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); occludin ( OCLN ); sulfide dehydrogenase like ( SQRDL ); acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); abhydrolase domain containing 11 ( ABHD11 ); acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); superoxide dismutase 2, mitochondrial ( SOD2 ); fucosidase, alpha-L- 1, tissue ( FUCA1 ); sideroflexin 3 ( SFXN3 ); carnitine palmitoyltransferase 2 ( CPT2 );
|
Protein
|
Humans
|
Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold)
|
Prognostic
|
LNCAP Cell Lines Vs LNCaP-SF (androgen independent)
|
NA
|
Cell Lines
|
23443136
|
|
1077
|
semenogelin I ( SEMG1 ); Cyclin-dependent kinase 1 ( CDC2 ); thymidine kinase 1, soluble ( TK1 ); semenogelin II ( SEMG2 ); barrier to autointegration factor 1 ( BANF1 ); cDNA FLJ16186 ( cDNA FLJ16186 ); polo-like kinase 1 ( PLK1 ); cyclin-dependent kinase 2 ( CDK2 ); insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); stathmin 1 ( STMN1 ); ribonucleotide reductase M2 ( RRM2 ); S100 calcium binding protein A13 ( S100A13 ); GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); neural cell adhesion molecule 2 ( NCAM2 ); thyroid hormone receptor interactor 13 ( TRIP13 ); ribonucleotide reductase M1 ( RRM1 ); nucleolar pre-rRNA processing protein ( ESF1 ); stathmin-like 2 ( STMN2 ); H3 histone, family 3A ( H3F3A ); GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); H2A histone family, member Z ( H2AFZ ); DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ATPase family, AAA domain containing 2 ( ATAD2 ); SCD6 homolog B (S. cerevisiae) ( LSM14B ); chromosome 13 open reading frame 33 ( C13orf33 ); karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); acireductone dioxygenase 1 ( ADI1 ); histone cluster 1, H4a ( HIST1H4A ); lamin B1 ( LMNB1 ); 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); phosphorylase, glycogen, liver ( PYGL ); PDZ binding kinase ( PBK ); histone cluster 1, H1b ( HIST1H1B ); histone acetyltransferase 1 ( HAT1 ); Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); H2A histone family, member Y ( H2AFY ); ligase I, DNA, ATP-dependent ( LIG1 ); structural maintenance of chromosomes 4 ( SMC4 ); topoisomerase (DNA) II beta 180kDa ( TOP2B ); nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); structural maintenance of chromosomes 2 ( SMC2 ); DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); Metastasis-associated protein 1 ( MTA1 );
|
Protein
|
Humans
|
Downregulated in LNCAP-SF [semenogelin I ( SEMG1 ); ( 0.076735 fold) Cyclin-dependent kinase 1 ( CDC2 ); ( 0.081925 fold) thymidine kinase 1, soluble ( TK1 ); ( 0.083392 fold) semenogelin II ( SEMG2 ); ( 0.10883 fold) barrier to autointegration factor 1 ( BANF1 ); ( 0.17609 fold) cDNA FLJ16186 ( cDNA FLJ16186 ); ( 0.19531 fold) polo-like kinase 1 ( PLK1 ); ( 0.20362 fold) cyclin-dependent kinase 2 ( CDK2 ); ( 0.22407 fold) insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); ( 0.22637 fold) stathmin 1 ( STMN1 ); ( 0.24713 fold) ribonucleotide reductase M2 ( RRM2 ); ( 0.25054 fold) S100 calcium binding protein A13 ( S100A13 ); ( 0.2628 fold) GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); ( 0.26922 fold) neural cell adhesion molecule 2 ( NCAM2 ); ( 0.26951 fold) thyroid hormone receptor interactor 13 ( TRIP13 ); ( 0.27195 fold) ribonucleotide reductase M1 ( RRM1 ); ( 0.27289 fold) nucleolar pre-rRNA processing protein ( ESF1 ); ( 0.27757 fold) stathmin-like 2 ( STMN2 ); ( 0.28292 fold) H3 histone, family 3A ( H3F3A ); ( 0.28744 fold) GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); ( 0.28965 fold) H2A histone family, member Z ( H2AFZ ); ( 0.2989 fold) DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ( 0.3037 fold) ATPase family, AAA domain containing 2 ( ATAD2 ); ( 0.30571 fold) SCD6 homolog B (S. cerevisiae) ( LSM14B ); ( 0.30649 fold) chromosome 13 open reading frame 33 ( C13orf33 ); ( 0.3127 fold) karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); ( 0.31541 fold) Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); ( 0.32372 fold) acireductone dioxygenase 1 ( ADI1 ); ( 0.33027 fold) histone cluster 1, H4a ( HIST1H4A ); ( 0.33313 fold) lamin B1 ( LMNB1 ); ( 0.33412 fold) 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); ( 0.33637 fold) phosphorylase, glycogen, liver ( PYGL ); ( 0.33849 fold) PDZ binding kinase ( PBK ); ( 0.34986 fold) histone cluster 1, H1b ( HIST1H1B ); ( 0.35951 fold) histone acetyltransferase 1 ( HAT1 ); ( 0.36643 fold) Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); ( 0.37213 fold) nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); ( 0.37728 fold) programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); ( 0.37993 fold) H2A histone family, member Y ( H2AFY ); ( 0.38303 fold) ligase I, DNA, ATP-dependent ( LIG1 ); ( 0.38796 fold) structural maintenance of chromosomes 4 ( SMC4 ); ( 0.38871 fold) topoisomerase (DNA) II beta 180kDa ( TOP2B ); ( 0.38889 fold) nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); ( 0.39627 fold) structural maintenance of chromosomes 2 ( SMC2 ); ( 0.3968 fold) DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); ( 0.39825 fold) Metastasis-associated protein 1 ( MTA1 ); ( 0.39986 fold) ]
|
Prognostic
|
LNCAP Cell Lines Vs LNCaP-SF (androgen independent)
|
NA
|
Cell Lines
|
23443136
|
|
1085
|
miR-183
|
miRNA
|
Humans
|
Upregulated in PC Cells
|
Diagnostic
|
Prostate Cancer Cell Lines Vs Normal Prostate Cell Lines
|
p<0.05
|
Cell Lines
|
23538390
|
|
1257
|
Occludin
|
mRNA
|
Humans
|
Downregulated in: [CAHPV-10 (19.08 fold); DU145 (3.2 fold); PC-3 (4.3 fold)]; Upregulated in LNCaP: (2.2 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
CAHPV-10 (p= 0.001); DU145 (p=0.003); PC-3 (0.003); LNCaP: (p = 0.001)
|
Cell Lines
|
24358122
|
|
1258
|
Claudin 1
|
mRNA
|
Humans
|
Downregulated in: [CAHPV-10 (10 fold); LNCaP: (100 fold); DU145 (2.1 fold); PC-3 (3.8 fold)];
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p = 0.001
|
Cell Lines
|
24358122
|
|
1259
|
Claudin 7
|
mRNA
|
Humans
|
Downregulated in: [DU145 (5.3 fold); PC-3 (24.8 fold)];Upregulated in LNCaP: (4.63 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
DU145 (p=0.004); PC-3 (p= 0.01); LNCaP (p = 0.001)
|
Cell Lines
|
24358122
|
|
1260
|
Claudin 7
|
mRNA
|
Humans
|
Downregulated in DU145 and PC-3
|
Prognostic
|
DU145, PC-3 Vs CAHPV-10
|
DU145 (p=0.02); PC-3 (p<0.001)
|
Cell Lines
|
24358122
|
|
1261
|
α-catenin
|
mRNA
|
Humans
|
Downregulated in: [DU145 (2.2 fold); PC-3 (33 fold)];
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p<0.001
|
Cell Lines
|
24358122
|
|
1262
|
α-catenin
|
mRNA
|
Humans
|
Downregulated in DU145 and PC-3
|
Prognostic
|
DU145, PC-3 Vs CAHPV-10
|
p<0.001
|
Cell Lines
|
24358122
|
|
1263
|
β-catenin
|
mRNA
|
Humans
|
Downregulated in: [CAHPV-10 (3 fold)] ;Upregulated in [LNCaP: (3.8 fold) DU145 (2.2 fold); PC-3 (2.1 fold)]
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
CAHPV-10 (p= 0.015); DU145 (p=0.001); PC-3 (p=0.001) LNCap: (p<0.001)
|
Cell Lines
|
24358122
|
|
1264
|
β-catenin
|
mRNA
|
Humans
|
Upregulated in DU145 and PC-3
|
Prognostic
|
DU145, PC-3 Vs CAHPV-10
|
DU145 (p=0.006); PC-3 (p=0.001)
|
Cell Lines
|
24358122
|
|
1265
|
E-Cadherin
|
mRNA
|
Humans
|
Downregulated in: [CAHPV-10 (2.3 fold) ; DU145 (5.6 fold); PC-3 (7.25 fold)]
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
CAHPV-10 (p= 0.004); DU145 (p<0.001); PC-3 (p<0.001);
|
Cell Lines
|
24358122
|
|
1266
|
Claudin 1
|
Protein
|
Humans
|
Downregulated in LNCaP (9.3 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p = 0.04
|
Cell Lines
|
24358122
|
|
1267
|
Claudin 7
|
Protein
|
Humans
|
Downregulated in LNCaP (1.1 fold); DU145 (1.1 fold); PC-3 (1.5 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p < 0.01
|
Cell Lines
|
24358122
|
|
1268
|
Claudin 7
|
Protein
|
Humans
|
Downregulated in CAHPV-10
|
Prognostic
|
CAHPV-10 Vs PC-3
|
p < 0.01
|
Cell Lines
|
24358122
|
|
1269
|
α-catenin
|
Protein
|
Humans
|
Downregulated in LNCaP (4.4 fold); DU145 (2 fold);
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
LNCaP: p = 0.03; DU145: p=0.04
|
Cell Lines
|
24358122
|
|
1270
|
E-cadherin
|
Protein
|
Humans
|
Downregulated in CAHPV-10 (1.7 fold); DU145 (1.5 fold); Upregulated in LNCaP: (2.7 fold)
|
Diagnostic
|
CAHPV-10, DU145, PC-3, LNCaP Vs PNT2
|
p < 0.01
|
Cell Lines
|
24358122
|
|
1271
|
ITGA3; ITGB1; TLN1; VCL; ITGA1; FLNC;
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
LNCaP Cell Lines Vs PC-3 Cell Lines
|
p<0.05
|
Cell Lines
|
24371517
|
|
1284
|
PDCD6IP; EEF1A2; FASN; VPS28; PABPC1;YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; ATP12A; CTNNB1; ENO1; HSPA5; KPNB1; PKM2; TPI1; YWHAE; SLC3A2; ARF1; CXADR; EHD4; HSP90AB2P; HSP90AB3P; IQGAP1; KRT9; KRT2; MFGE8; PARK7; PGK1; PRDX1; RAB10; RAB1A;RAP1A; AHCY; TUBA1A; CCT5; UGDH;
|
Protein
|
Humans
|
Upregulated in PC346C cell lines (log2 fold):Downregulated in PC346C cell lines (log2 fold): []
|
Diagnostic
|
PC346C vs PNT2C2
|
p<0.05
|
Cell Lines
|
24391718
|
|
1285
|
PDCD6IP; EEF1A2; FASN; UBA52; VPS28; ACTR3B; CD9; YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6 ;F11R; ATP12A; CTNNB1; ENO1;KPNB1; PKM2; TPI1; YWHAE; SLC3A2; EHD4; PTGFRN; HSP90AB2P; HBB; KRT9; KRT2; MFGE8; PARK7; RAB1A; RAC1; AHCY; CCT5;
|
Protein
|
Humans
|
Upregulated in PC346C cell lines (log2 fold):Downregulated in PC346C cell lines (log2 fold): []
|
Diagnostic
|
PC346C vs RWPE
|
p<0.05
|
Cell Lines
|
24391718
|
|
1286
|
PDCD6IP; UBA52; BCAM; PABPC1; YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; ATP12A; CTNNB1; ENO1; HSPA5; KPNB1; PKM2; TPI1; ARF1; CD151; CXADR; HSP90AB3P; IQGAP1; PGK1; PRDX1; RAB10; RAP1A; TUBA1A; UGDH;
|
Protein
|
Humans
|
Upregulated in VCaP cell lines (log2 fold): Downregulated in VCaP cell lines (log2 fold): []
|
Diagnostic
|
VCaP vs PNT2C2
|
p<0.05
|
Cell Lines
|
24391718
|
|
1287
|
PDCD6IP; EEF1A2; FASN; UBA52; VPS28; ACTR3B; BCAM; CD9;YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; HSPA5; YWHAQ; CD151; PTGFRN; HBB; RAC1;
|
Protein
|
Humans
|
Upregulated in VCaP cell lines (log2 fold): Downregulated in VCaP cell lines (log2 fold): []
|
Diagnostic
|
VCaP vs RWPE
|
p<0.05
|
Cell Lines
|
24391718
|
|
1382
|
miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a; miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429
|
miRNA
|
Humans
|
Upregulated in docetaxel-resistant cell lines: [miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a];Downreegulated in docetaxel-resistant cell lines: [miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429]
|
Prognostic
|
PC3 Cell Line Vs PC3Rx Cell Line (docetaxel-resistant sublines)
|
p≤0.001
|
Cell Lines
|
24714754
|
|
1383
|
miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p; miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p;
|
miRNA
|
Humans
|
Upregulated in docetaxel-resistant cell lines: [miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p;]Downregulated in docetaxel-resistant cell lines: [miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p;]
|
Prognostic
|
DU145 Cell Line Vs DU145Rx Cell Line(docetaxel-resistant sublines)
|
p≤0.001
|
Cell Lines
|
24714754
|
|
1424
|
miR-7; miR-221; miR-222
|
miRNA
|
Humans
|
Upregulated in PC-3 Cell Lines: [ miR-7(11.3 fold); miR-222 (8.6 fold); miR-221 (8.6 fold)]
|
Prognostic
|
LNCaP Cell Lines Vs PC-3 Cell Lines
|
p<0.05
|
Cell Lines
|
24760272
|
|
1547
|
STEAP2 (Six transmembrane epithelial antigen of the prostate)
|
Protein
|
Humans
|
Upregulated in DU145 and PC3 (28 fold)
|
Diagnostic
|
Cancerous Vs Non Cancerous Cell Lines
|
p<0.001
|
Cell Lines
|
25248617
|
|
1586
|
AF087978; uc002llc; EF177379; BC013821; uc001pyz; AK024556; AB116553; BC012900; LOC100506303; LOC100506922y; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813;
|
LncRNA
|
Humans
|
Upregulated in PC3 (Log Fold Change) [AF087978 (5.8 fold) ; uc002llc(4.8 fold) ; EF177379(4.3 fold) ; BC01382(3.8 fold)1 ; uc001pyz(3.7 fold) ; AK024556 (3.7 fold) ; AB116553 (3.5 fold) ; BC012900 (3.5 fold) ; LOC100506303(2.6 fold) ; LOC100506922(3.6 fold); LOC100287482 (3.0 fold); XLOC_l2_009441 (3.3 fold); LOC154822 (3.2 fold) ; XLOC_010807(3.5 fold) ; XLOC_002335 (3.4 fold); XLOC_l2_009136(2.1 fold); XLOC_002871 (2.3 fold); ANKRD20A9P ( 2.0 fold) ; FLJ20444 (4.1 fold); XLOC_003734( 4.0 fold); LOC100505666(2.1 fold); LOC100506411(4.1 fold); XLOC_007697(3.4 fold); XLOC_003734y(3.5 fold) XLOC_l2_000735(4.6 fold); LOC100129480(4.5 fold); XLOC_007162(3.1 fold); LOC100506802(3.4 fold); LOC100507025(5.7 fold); XLOC_010813(3.8 fold;]
|
Diagnostic
|
PC3 Cells Vs prostate epithelial cells
|
p<0.05
|
Cell Lines
|
25307116
|
|
1587
|
LOC100506303; LOC100506922; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813;
|
LncRNA
|
Humans
|
Upregulated in LNCaP (log fold change): [LOC100506303(5.1 fold); LOC100506922y(4.9 fold); LOC100287482(4.8 fold) ; XLOC_l2_009441(4.7 fold); LOC154822(4.6 fold); XLOC_010807 (4.5 fold) ; XLOC_002335( 4.5 fold) ; XLOC_l2_009136(4.4 fold) ; XLOC_002871( 4.2 fold) ; ANKRD20A9(4.0 fold); FLJ20444(4.0 fold); XLOC_003734(3.8 fold) ; LOC100505666(3.7 fold) ; LOC10050641( 3.5 fold)1; XLOC_007697(3.3 fold); XLOC_003734y(3.2 fold); XLOC_l2_000735(2.8 fold); LOC100129480(2.4 fold); XLOC_007162(2.2 fold); LOC100506802(2.1 fold) ; LOC100507025(2.1 fold) ; XLOC_010813(2.1 fold) ;]
|
Diagnostic
|
LNCaP Cells Vs prostate epithelial cells
|
p<0.05
|
Cell Lines
|
25307116
|
|
1663
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in T2 PCa and T3+T4 PCa
|
Diagnostic
|
Normal Cell Lines Vs PCa Cell Lines
|
p<0.001
|
Cell Lines
|
30911973
|
|
1853
|
miR-425-5p
|
miRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Adjacent Normal
|
p<0.001
|
Cell Lines
|
30720162
|